Abstract: It is an object of the present invention to identify a novel analog of carbacyclic phosphatidic acid that is a cyclic phosphatidic acid derivative, and to clarify the physiological activity thereof. According to the present invention, a compound represented by the following formula (1) is provided: wherein R represents a linear or branched alkyl group containing 1 to 30 carbon atoms, a linear or branched alkenyl group containing 2 to 30 carbon atoms, or a linear or branched alkynyl group containing 2 to 30 carbon atoms, and these groups may optionally comprise a cycloalkane ring or an aromatic ring; and M represents a hydrogen atom or a counter cation.

Abstract: It is an object of the present invention to provide a novel therapeutic agent for demyelinating disease which has an action to suppress demyelination of nerve axons. According to the present invention, a therapeutic agent for demyelinating disease which comprises cyclic phosphatidic acids, carba-cyclic phosphatidic acids, thia-cyclic phosphatidic acids, or a salt thereof is provided.

Abstract: It is an object of the present invention to provide a novel therapeutic agent for demyelinating disease which has an action to suppress demyelination of nerve axons. According to the present invention, a therapeutic agent for demyelinating disease which comprises cyclic phosphatidic acids, carba-cyclic phosphatidic acids, thia-cyclic phosphatidic acids, or a salt thereof is provided.

Abstract: This invention provides a therapeutic agent for arthrosis exerting inhibitory effects on articular cartilage destruction and high therapeutic effects on arthrosis. The invention provides a therapeutic agent for arthrosis which comprises, as an active ingredient, cyclic phosphatidic acid or carbacyclic phosphatidic acid.

Abstract: This invention provides a therapeutic agent for arthrosis exerting inhibitory effects on articular cartilage destruction and high therapeutic effects on arthrosis. The invention provides a therapeutic agent for arthrosis which comprises, as an active ingredient, cyclic phosphatidic acid or carbacyclic phosphatidic acid.

Abstract: An object is to provide a means which is useful for the development of an anti-malaria agent. It was found that a mitochondrial DNA polymerase of falciparum malaria shows a bivalent iron ion requirement. Thus, disclosed is a method for measuring the activity of a DNA polymerase, including the steps of: (1) incubating a solution containing a bivalent iron ion, a mitochondrial DNA polymerase of falciparum malaria, template DNA, and at least one deoxyribonucleoside triphosphate or deoxyribonucleoside triphosphate derivative; (2) detecting the synthesized double-stranded DNA; and (3) calculating the activity of the DNA polymerase from the result of the detection carried out in step (2).

Abstract: An object of the present invention is to elucidate an analgesic effect as one of new cPA bioactivities and thus to provide a novel analgesic agent. The present invention provides an analgesic agent which comprises a cyclic phosphatidic acid derivative that is one type of phospholipid.

Abstract: An object of the present invention is to elucidate an analgesic effect as one of new cPA bioactivities and thus to provide a novel analgesic agent. The present invention provides an analgesic agent which comprises a cyclic phosphatidic acid derivative that is one type of phospholipid.

Abstract: An object of the present invention is to elucidate an analgesic effect as one of new cPA bioactivities and thus to provide a novel analgesic agent. The present invention provides an analgesic agent which comprises a cyclic phosphatidic acid derivative that is one type of phospholipid.

Abstract: It is an object of the present invention to synthesize a carba cyclic phosphatidic acid derivative having a novel structure by substituting O at position sn-2 of the glycerol skeleton with CH2, and study the action of the obtained derivative to suppress cancer cell invasion. The present invention provides a compound represented by the following formula (I): wherein R represents a linear or branched alkyl group containing 1 to 30 carbon atoms, a linear or branched alkenyl group containing 2 to 30 carbon atoms, or a linear or branched alkynyl group containing 2 to 30 carbon atoms, wherein these groups may comprise a cycloalkane ring or aromatic ring; and M represents a hydrogen atom or counter cation.

Abstract: It is an object of the present invention to synthesize a carba cyclic phosphatidic acid derivative having a novel structure by substituting O at position sn-2 of the glycerol skeleton with CH2, and study the action of the obtained derivative to suppress cancer cell invasion. The present invention provides a compound represented by the following formula (I): wherein R represents a linear or branched alkyl group containing 1 to 30 carbon atoms, a linear or branched alkenyl group containing 2 to 30 carbon atoms, or a linear or branched alkynyl group containing 2 to 30 carbon atoms, wherein these groups may comprise a cycloalkane ring or aromatic ring; and M represents a hydrogen atom or counter cation.

Abstract: An object of the present invention is to provide a novel medicament which is useful for treating and/or preventing a nerve disease by increasing the survival rate of nerve cells or promoting the elongation of nerve cells. According to the present invention, there is provided a medicament for promoting the survival of nerve cells, which comprises a cyclic phosphatidic acid derivative having a cyclic phosphoric acid structure at the sn-2 and 3 positions of glycerol.

Abstract: An object of the present invention is to provide a novel agent for suppression of cancer metastasis by studying the suppressing action of cancer cell invasion by carbacyclic phosphatidic acid derivatives.

Abstract: An object of the present invention is to reveal an action of cPA on glial cells as a new physiological activity of cPA and to reveal the possibility of cPA as a medicament for treating a brain nerve disease including Alzheimer's disease, ischemic nerve disease, and Parkinsonism, and particularly cerebrovasucular dementia such as Binswanger's disease type dementia. According to the present invention, there is provided a medicament for treating cerebrovascular dementia, which comprises a cyclic phosphatidic acid derivative having a cyclic phosphoric acid structure at the sn-2 and 3 positions of glycerol.